Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218
Gynecologic Oncology Aug 16, 2019
Wade KNS, Brady MF, Thai T, et al. - A prospective phase 3 trial (GOG 218) was undertaken to assess the link between measurements of adiposity (BMI, surface fat area, and visceral fat area [VFA]) and prognosis for oncologic outcomes among patients treated with chemotherapy, with or without bevacizumab (BEV), an anti-angiogenic agent. The ultimate goal was to find whether adiposity interferes with the activity of BEV. Researchers analyzed computed tomography scans taken prior to treatment for 1,538 GOG 218 participants. Findings revealed a strong correlation between measures of adiposity. However, the effectiveness of BEV was not predicted by measures of adiposity. In this study, VFA was identified as a weak prognostic factor.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries